Abstract:
|
Since 2014, GlaxoSmithKline (GSK) has been using formal prior elicitation methods to support internal decision making and analysis in drug development. Prior elicitation is used to enable quantification of existing knowledge about an asset in the absence of directly relevant data. In this talk, I will provide a brief introduction to the methods that GSK have been using for prior elicitation, and discuss some of the benefits and challenges of conducting prior elicitations. I will also gives some examples of how resulting quantitative belief distribution (or elicited prior) can be utilized.
|